Immunomodulating drugs immunosuppressants

QUINUPRISTIN/ DALFOPRISTIN ANTICANCER AND IMMUNOMODULATING DRUGS -CICLOSPORIN t plasma concentrations of immunosuppressants, t risk of infections and toxic effects of cidosporin Due to inhibition of CYP3A4-mediated metabolism of cidosporin Monitor renal function prior to concurrent therapy, and blood count and cidosporin levels during therapy. Warn patients to report symptoms (fever, sore throat) immediately... 

Immunomodulators—substances (nutrients, allergens, some food components, herbs, and drugs) that can affect the immune system function. There are two types of such substances depending on their effects immunosuppressants and immunostimulators. 

Figure 3.3.1-2 Application of the TDAR assay in immunotoxicity assessment. When evaluating unintended immunosuppression, the TDAR assay may be conducted when evidence of immunotoxicity is seen in repeated-dose toxicity studies. In these instances, the assay should be conducted prior to Phase 3 or earlier, depending on factors such as the severity of the findings and the intended patient population. The TDAR assay also could be used early in the drug development process to screen for immunotoxicity potential. This approach may be useful particularly to help de-risk unintended off-target immunomodulation or when a novel target/mechanisms may alter immune function.

Poriatin, a low-molecular-weight triterpene from Poria coccus, has immunomodulating properties. It has demonstrated antiviral activity and increased production of macrophages and other immune cells. It has also demonstrated immunosuppressive activity, reducing the severity of induced autoimmune encephalitis in conjunction with a standard autoimmune drug. Poriatin is a known aldosterone antagonist (Hobbs 1995). 

---